Powder: -20°C for 3 years | In solvent: -80°C for 1 year
JR-AB2-011 是一种选择性 mTORC2抑制剂,IC50值为 0.36 μM。JR-AB2-011 通过阻断 Rictor-mTOR 联合体 (Ki: 0.19 μM) 抑制 mTORC2 活性,并且具有抗多形性胶质母细胞瘤 (GBM) 的活性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 666 | 现货 | ||
5 mg | ¥ 1,630 | 现货 | ||
10 mg | ¥ 2,630 | 现货 | ||
25 mg | ¥ 4,470 | 现货 | ||
50 mg | ¥ 6,370 | 现货 | ||
100 mg | ¥ 8,730 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,790 | 现货 |
产品描述 | JR-AB2-011 is a selective mTORC2 inhibitor with an IC 50 value of 0.36 μM. JR-AB2-011 inhibits mTORC2 activity by blocking Rictor-mTOR association ( K i : 0.19 μM) and is cytotoxic in glioblastoma [1]. |
靶点活性 | mTORC2:0.36 μM |
体外活性 | JR-AB2-011 (1 μM; 24 hours) shows good anti-GBM properties, blocks mTORC2 signaling and Rictor association with mTOR [1]. JR-AB2-011 (0.5-2 μM; 48 hours) displays the least toxicity to normal neurons with no significant cytotoxic effects for concentrations up to 10 mM compared to CID613034 [1]. Apoptosis Analysis [1] Cell Line: U87 GBM cells; LN229 GBM cells Concentration: 1 μM Incubation Time: 24 hours Result: Had good anti-GBM properties and blocked mTORC2 signaling and Rictor association with mTOR. Cell Cytotoxicity Assay [1] Cell Line: Normal mature human neurons Concentration: 0.5, 1, 2 μM Incubation Time: 48 hours Result: Displayed the least toxicity to normal neurons with no significant cytotoxic effects for concentrations up to 10 mM. |
体内活性 | Mice receiving JR-AB2-011 (4 mg/kg; daily i.p. for 10 days; 20 mg/kg; daily i.p. for 10 days) at either dosing regimen show significant inhibition of tumor growth rate (JR-AB2-011 at 4 mg/kg/d; 74% inhibition at end of dosing period; tumor growth delay 10.0 days; JR-AB2-011 at 20 mg/kg/d; 80% inhibition at end of dosing period; tumor growth delay 12.0 days) as compared to mice receiving vehicle alone [1]. Animal Model: LN229 cells in female C.B.-17-scid (Taconic) mice [1] Dosage: 4 mg/kg; 20 mg/kg Administration: Daily i.p.; 10 days Result: Either dosing regimen displayed marked inhibition of tumor growth rate as compared to mice receiving vehicle alone. |
分子量 | 398.28 |
分子式 | C17H14Cl2FN3OS |
CAS No. | 2411853-34-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 61.5 mg/mL(154.41 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.5108 mL | 12.554 mL | 25.108 mL | 62.7699 mL |
5 mM | 0.5022 mL | 2.5108 mL | 5.0216 mL | 12.554 mL | |
10 mM | 0.2511 mL | 1.2554 mL | 2.5108 mL | 6.277 mL | |
20 mM | 0.1255 mL | 0.6277 mL | 1.2554 mL | 3.1385 mL | |
50 mM | 0.0502 mL | 0.2511 mL | 0.5022 mL | 1.2554 mL | |
100 mM | 0.0251 mL | 0.1255 mL | 0.2511 mL | 0.6277 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
JR-AB2-011 2411853-34-2 PI3K/Akt/mTOR signaling mTOR JRAB2011 JR-AB-2-011 JR AB2 011 Inhibitor inhibitor inhibit